Osteoblastic 11β-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure

被引:158
|
作者
Cooper, MS
Rabbitt, EH
Goddard, PE
Bartlett, WA
Hewison, M
Stewart, PM
机构
[1] Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England
[2] Birmingham Heartlands & Solihull NHS Trust, Dept Clin Biochem & Immunol, Birmingham, W Midlands, England
关键词
11 beta-hydroxysteroid dehydrogenase; bone; osteoblasts; glucocorticoids; cortisol; osteoporosis; aging;
D O I
10.1359/jbmr.2002.17.6.979
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The risk of glucocorticoid-induced osteoporosis increases substantially with age but there is considerable individual variation. In recent studies we have shown that the effects of glucocorticoids on bone are dependent on autocrine actions of the enzyme 1113-hydroxysteroid dehydrogenase type 1 (11beta-HSD1); expression of 11beta-HSD1 in osteoblasts (OBs) facilitates local synthesis of active glucocorticoids with consequent effects on osteoblastic proliferation and differentiation. Using primary cultures of human OBs, we have now characterized the age-specific variation in osteoblastic 11beta-HSD1 and defined enzyme kinetics and regulation using natural and therapeutic glucocorticoids. 11beta-HSD1 reductase activity (cortisone to cortisol conversion) was recognized in all OB cultures and correlated positively with age (r = 0.58 with all cultures, p < 0.01, and n = 18; r = 0.87 with calcaneal-derived cultures, p < 0.001, and n = 14). Glucocorticoid treatment caused a time- and dose-dependent increase in 11beta-HSD1 activity over control (e.g., dexamethasone [DEX; 1 muM], 2.6-fold +/-0.5 (mean +/- SE),p < 0.001, and n = 16; cortisol (100 nM), 1.7-fold +/- 0.1, p < 0.05, and n = 14). Similar increases in 11beta-HSD1 mRNA expression were indicated using real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) analyses (3.5-fold with DEX, p < 0.01; 2.5-fold with cortisol, p < 0.05). The capacity of 11beta-HSD1 to metabolize the synthetic glucocorticoids prednisone and prednisolone was investigated in human OBs (hOBs) and fetal kidney-293 cells stably transfected with human 11beta-HSD1 cDNA. Transfected cells and hOBs were able to interconvert prednisone and prednisolone with reaction kinetics indistinguishable from those for cortisone and cortisol. To assess the in vivo availability of substrates for osteoblastic 11beta-HSD1, plasma cortisone and prednisone levels were measured in normal males before and after oral prednisolone (5 mg). The 9:00 a.m. serum cortisone levels were 110 +/- 5 nmol/liter and prednisone levels peaked at 78 +/- 23 nmol/liter 120 minutes after administration of prednisolone. Thus, therapeutic use of steroids increases substrate availability for 11beta-HSD1 in bone. These studies indicate that activation of glucocorticoids at an autocrine level within bone is likely to play an important role in the age-related decrease in bone formation and increased risk of glucocorticoid-induced osteoporosis.
引用
收藏
页码:979 / 986
页数:8
相关论文
共 50 条
  • [31] Synergistic induction of osteoblastic 11β-hydroxysteroid dehydrogenase type 1 by inflammatory cytokines and glucocorticoids:: A novel mechanism for glucocorticoid-induced bone disease.
    Cooper, MS
    Kaur, K
    Hardy, R
    Buckley, CD
    Stewart, PM
    Hewison, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S91 - S92
  • [32] The ratio of 11-hydroxysteroid dehydrogenase 1/11-hydroxysteroid dehydrogenase 2 predicts glucocorticoid response in nasal polyps
    Jiang, Lijie
    Zhou, Min
    Deng, Jie
    Sun, Yueqi
    Zuo, Kejun
    Zheng, Rui
    Shi, Jianbo
    Lai, Yinyan
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2019, 276 (01) : 131 - 137
  • [33] Impaired 11β-Hydroxysteroid Dehydrogenase Type 2 in Glucocorticoid-Resistant Patients
    Vitellius, Geraldine
    Delemer, Brigitte
    Caron, Philippe
    Chabre, Olivier
    Bouligand, Jerome
    Pussard, Eric
    Trabado, Severine
    Lombes, Marc
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (11): : 5202 - 5213
  • [34] 11β-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone
    Cooper, MS
    Blumsohn, A
    Goddard, PE
    Bartlett, WA
    Shackleton, CH
    Eastell, R
    Hewison, M
    Stewart, PM
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (08): : 3874 - 3877
  • [35] UVB induces epidermal 11β-hydroxysteroid dehydrogenase type 1 activity in vivo
    Tiganescu, Ana
    Hupe, Melanie
    Jiang, Yan J.
    Celli, Anna
    Uchida, Yoshikazu
    Mauro, Theodora M.
    Bikle, Daniel D.
    Elias, Peter M.
    Holleran, Walter M.
    EXPERIMENTAL DERMATOLOGY, 2015, 24 (05) : 370 - 376
  • [36] Piper sarmentosum Prevents Glucocorticoid-Induced osteoporotic Bone Resorption by Increasing 11β-Hydroxysteroid Dehydrogenase Type 1 Activity
    Suhana, M. R. Elvy
    Farihah, H. S.
    Faizah, O.
    Nazrun, S. Ahmad
    Norazlina, M.
    Norliza, M.
    Nirwana, S. Ima
    CLINICA TERAPEUTICA, 2011, 162 (04): : 313 - 318
  • [37] The 11 beta-hydroxysteroid dehydrogenase system, a determinant of glucocorticoid and mineralocorticoid action - Role of type-1 11 beta-hydroxysteroid dehydrogenase in detoxification processes
    Maser, E
    Oppermann, UCT
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 249 (02): : 365 - 369
  • [38] GLUCOCORTICOID EXCESS INCREASES THE NUMBER OF BONE MARROW ADIPOCYTES WITHOUT CHANGING 11β-HYDROXYSTEROID DEHYDROGENASE TYPE I EXPRESSION
    Camozzi, Valentina
    Franzin, Chiara
    Ballanti, Paola
    Pagano, Claudio
    Zaninotto, Martina
    Vettor, Roberto
    Mantero, Franco
    Luisetto, Giovanni
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : 160 - 160
  • [39] 11β-hydroxysteroid dehydrogenase type 2 activity in rat osteosarcoma cells:: Autocrine regulation of glucocorticoid induction of osteoblast activity
    Eyre, LJ
    Bland, R
    Hughes, SV
    Sheppard, MC
    Stewart, PM
    Hewison, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (09) : 1503 - 1503
  • [40] Placental 11 beta-hydroxysteroid dehydrogenase: A key regulator of fetal glucocorticoid exposure
    Benediktsson, R
    Calder, AA
    Edwards, CRW
    Seckl, JR
    CLINICAL ENDOCRINOLOGY, 1997, 46 (02) : 161 - 166